v3.26.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Operating activities    
Net income $ 216,122 $ 118,708
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and finance lease amortization 53,189 43,292
Amortization of intangible assets 61,195 51,170
Amortization of deferred financing costs and original issue discount 1,081 1,278
Change in fair value of investments (4,542) 11,471
Deferred income tax expense (benefit) 26,447 (18,668)
Share-based compensation expense [1] 27,447 26,360
Loss on disposal of assets 211 602
Loss attributable to business dispositions 18,238 3,905
Other noncash charges 2,159 1,513
Excess tax benefits from equity awards (3,447) 90
Net changes in operating assets and liabilities:    
Accounts receivable (64,430) (485)
Inventories 14,869 (199,279)
Other assets (105,336) 7,990
Accounts payable 116,387 129,489
Accrued wages and employee benefits (8,098) (28,297)
Other accrued liabilities (110,996) (18,798)
Net cash provided by operating activities 240,496 130,341
Investing activities    
Proceeds from sale of property and equipment 10 0
Purchase of long-term investments 0 (2,656)
Expenditures for property and equipment (87,687) (88,653)
Acquisition of businesses, net of cash acquired (211,820) 0
Proceeds (payments) from sale of businesses, net of cash disposed 23,654  
Proceeds (payments) from sale of businesses, net of cash disposed   (1,999)
Net cash used in investing activities (275,843) (93,308)
Financing activities    
Proceeds from short-term borrowings 22,736 21,860
Proceeds from long-term borrowings 82,538 92,585
Repayments of short-term borrowings (25,571) (30,171)
Repayments of long-term borrowings and finance lease obligations (93,096) (29,032)
Stock repurchases 0 (147,917)
Payment of deferred acquisition consideration (958) 0
Cash dividends paid to noncontrolling interest of subsidiary 0 (293)
Taxes paid related to equity awards (36,702) (9,393)
Proceeds from the exercise of stock options 10,275 1,043
Net cash used in financing activities (40,778) (101,318)
Effect of foreign exchange rate changes on cash and cash equivalents (367) 6,539
Net decrease in cash and cash equivalents (76,492) (57,746)
Cash and cash equivalents at beginning of period 341,413 281,277
Cash and cash equivalents at end of period $ 264,921 $ 223,531
[1] Represents share-based compensation expense to account for stock options, restricted stock, and other stock awards over their respective vesting periods.